ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 6
Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).
Video content above is prompted by the following:
- How have you adapted your treatment approach given the efficacy and safety profiles from trials discussed above?
- How do the updated data fit in or challenge NCCN Guidelines?
- What clinical implications can be found from real-world evidence?
Related Content:
